Why is Twist Bioscience stock sliding today?
Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.
How this was made
The 30-second read
Why it matters
Investors appear to be repricing the gap between top-line momentum and profitability improvement, with prior analyst positioning mixed and no recent EPS revision tailwind.
Market read
A concrete earnings print with a negative EPS surprise is the immediate catalyst, and the article highlights persistence of the issue.
What to watch
The article does not provide guidance, margin drivers, or cash flow details, which could change the earnings call narrative and reduce the selloff.
Background
The piece frames today’s drop as a continuation of a recurring EPS-miss pattern despite revenue growth.
Ticker impact
Twist Bioscience shares fell 4.2% pre-open after fiscal Q3 EPS missed consensus while revenue beat, reviving concerns about profitability progress.
Bearish bias for the next session and into the earnings call as investors focus on persistent EPS misses despite top-line growth.
The article cites a specific EPS loss of $0.56 vs $0.48 consensus and notes similar EPS misses in Q1 and Q2 FY2026, plus lack of positive EPS revisions over 90 days.
Market effects
Reinforces investor sensitivity in synthetic biology to profitability timelines, not just revenue growth.
No specific regional spillover described beyond US pre-open reaction.
No direct global macro or cross-border catalyst described.
Counterpoint
Revenue beat suggests commercial momentum; the market may be over-penalizing near-term EPS optics versus longer-cycle DNA synthesis adoption.
Key entities
- companyTwist Bioscience
Synthetic biology company whose fiscal Q3 results missed EPS expectations while revenue beat, driving a pre-open decline.
- analyst_firmEvercore ISI
Downgraded the stock to In Line from Outperform in early July, per the article.
- analyst_firmLeerink
Raised price targets in mid-July, per the article.
- analyst_firmCanaccord
Raised price targets in mid-July, per the article.
